

# Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/112275/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Kentala, Henriikka, Koponen, Annika, Vihinen, Helena, Pirhonen, Juho, Pirhonen, Juho, Liebisch, Gerhard, Pataj, Zoltan, Kivelä, Annukka, Li, Shiqian, Karhinen, Leena, Jääskeläinen, Eeva, Andrews, Robert, Meriläinen, Leena, Matysik, Silke, Ikonen, Elina, Zhou, You ORCID: <https://orcid.org/0000-0002-1743-1291>, Jokitalo, Eija and Olkkonen, Vesa M. 2018. OSBP-related protein-2 (ORP2): a novel Akt effector that controls cellular energy metabolism. *Cellular and Molecular Life Sciences* 75 (21) , pp. 4041-4057. file

Publishers page: <http://dx.doi.org/10.1007/s00018-018-2850-8>  
<<http://dx.doi.org/10.1007/s00018-018-2850-8>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



[Click here to view linked References](#)

## OSBP-related protein-2 (ORP2): A novel Akt effector that controls cellular energy metabolism

Henriikka Kentala<sup>a</sup>, Annika Koponen<sup>a</sup>, Helena Vihinen<sup>b</sup>, Juho Pirhonen<sup>a,c</sup>, Gerhard Liebisch<sup>d</sup>, Zoltan Pataj<sup>d</sup>, Annukka Kivelä<sup>a</sup>, Shiqian Li<sup>a,c</sup>, Leena Karhinen<sup>c</sup>, Eeva Jääskeläinen<sup>a</sup>, Robert Andrews<sup>e</sup>, Leena Meriläinen<sup>b</sup>, Silke Matysik<sup>d</sup>, Elina Ikonen<sup>a,c</sup>, You Zhou<sup>a,e,f</sup>, Eija Jokitalo<sup>b</sup>, and Vesa M. Olkkonen<sup>a,c\*</sup>

<sup>a</sup>*Minerva Foundation Institute for Medical Research, FI-00290 Helsinki, Finland*

<sup>b</sup>*Electron Microscopy Unit, Institute of Biotechnology, FI-00014 University of Helsinki, Helsinki, Finland*

<sup>c</sup>*Department of Anatomy, Faculty of Medicine, FI-00014 University of Helsinki, Finland*

<sup>d</sup>*Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, D-93053 Regensburg, Germany*

<sup>e</sup>*Systems Immunity Research Institute, Cardiff University, Cardiff, CF14 4XN, UK*

<sup>f</sup>*Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, CF14 4XN, UK*

\*Corresponding author. Minerva Foundation Institute for Medical Research, Biomedicum 2U, Tukholmankatu 8, FI-00290 Helsinki, Finland. E-mail: [vesa.olkkonen@helsinki.fi](mailto:vesa.olkkonen@helsinki.fi) (V.M. Olkkonen)

### Abbreviations

CRISPR	clustered regularly interspaced short palindromic repeats
ECAR	extracellular acidification rate
EM	electron microscopy
ER	endoplasmic reticulum
FA	fatty acid
GSK	glycogen synthase kinase
HUVEC	human umbilical vein endothelial cell
IPA	Ingenuity® pathway analysis
KO	knock-out

1		
2		
3		
4	LD	lipid droplet
5		
6	LDL	low-density lipoprotein
7		
8	OSBP	oxysterol-binding protein
9		
10	ORP	OSBP-related protein
11		
12	PIP	phosphatidylinositol phosphate
13		
14	TEM	transmission electron microscopy
15		
16	TG	triacylglycerol
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
61		
62		
63		
64		
65		

1  
2  
3  
4 **Abstract**  
5  
6

7 ORP2 is a ubiquitously expressed OSBP-related protein previously implicated in  
8 endoplasmic reticulum (ER) – lipid droplet (LD) contacts, triacylglycerol (TG)  
9 metabolism, cholesterol transport, adrenocortical steroidogenesis, and actin-dependent  
10 cell dynamics. Here, we characterize the role of ORP2 in carbohydrate and lipid  
11 metabolism by employing ORP2-knock-out (KO) hepatoma cells (HuH7) generated by  
12 CRISPR-Cas9 gene editing. The ORP2-KO and control HuH7 cells were subjected to  
13 RNA sequencing, analyses of Akt signaling, carbohydrate and TG metabolism, the  
14 extracellular acidification rate, and the lipidome, as well as to transmission electron  
15 microscopy.  
16  
17

18 The loss of ORP2 resulted in a marked reduction of active phosphorylated  
19 Akt(Ser473) and its target Glycogen synthase kinase 3 $\beta$ (Ser9), consistent with defective  
20 Akt signaling. ORP2 was found to form a physical complex with the key controllers of  
21 Akt activity, Cdc37 and Hsp90, and to co-localize with Cdc37 and active Akt(Ser473) at  
22 lamellipodial plasma membrane regions, in addition to the previously reported ER–LD  
23 localization. ORP2-KO reduced glucose uptake, glycogen synthesis, glycolysis, mRNAs  
24 encoding glycolytic enzymes, and SREBP-1 target gene expression, and led to defective  
25 TG synthesis and storage. ORP2-KO did not reduce but rather increased ER–LD contacts  
26 under basal culture conditions but interfered with their expansion upon fatty acid loading.  
27  
28

29 Together with our recently published work (Kentala et al., FASEB J 2017, Nov 1.  
30 PMID: 29092904), this study identifies ORP2 as a new regulatory nexus of Akt signaling,  
31 cellular energy metabolism, actin cytoskeletal function, cell migration and proliferation.  
32  
33

34 **Keywords** Akt signaling; CRISPR-Cas9; glycolysis; OSBPL2; OSBP-related protein;  
35 triacylglycerol  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Introduction

Oxysterol binding protein (OSBP)-related protein 2 (ORP2) belongs to a conserved family of ubiquitous lipid-binding/transfer proteins, characterized by a carboxy-terminal OSBP-related lipid-binding domain (ORD). In addition, most ORPs contain an amino-terminal pleckstrin homology (PH) domain that binds membrane phosphoinositides (PIPs) and a two phenylalanines in an acidic tract (FFAT) motif which targets the ORPs to the ER membranes via interaction with the the integral VAMP-associated proteins (VAPs) [28, 37]. The ORD of several ORPs binds cholesterol, oxysterols, or phosphatidylserine (PS) and additionally PI4P or other PIPs [8, 11, 17, 30, 31, 34, 48]. Recent hallmark studies have established that a number of ORPs have the capacity to mediate the counter-current transport of cholesterol or PS in exchange for PIPs, a process in which the synthesis and hydrolysis of PIPs energizes the transport of cholesterol or PS against their concentration gradients [8, 31, 32, 34]. For the founder member of the ORP family, OSBP, it was shown that its highest-affinity oxysterol ligand, 25-hydroxycholesterol (25OHC) inhibits the function of the protein as a bidirectional cholesterol/PI4P transporter at ER-Golgi contacts [31].

ORP2 is a cytosolic protein which lacks the membrane-targeting PH domain but is found to transiently localize on the surface of the intracellular lipid droplets and to ER-LD contacts [16, 22]. In cells lacking large lipid droplets or after treatment with the high-affinity oxysterol ligand of ORP2, 22(R)-hydroxycholesterol [22(R)OHC], the protein is often found in the cortical region of the cells [16, 22]. The cellular function of ORP2 was previously linked to cholesterol and triacylglycerol (TG) homeostasis. ORP2 is found to bind cholesterol, 22(R)OHC, 25OHC and 7-ketocholesterol (7KC) [16, 47]. Furthermore, ORP2 was reported to bind lipid vesicles containing phosphatidylinositol phosphates (PIPs) [15]. In HeLa cells ORP2 overexpression was shown to increase the efflux of [<sup>14</sup>C]cholesterol and enhance its intracellular transport [15]. In adrenocortical cells, silencing of ORP2 was shown to increase the levels of cholesterol and to reduce 22(R)OHC and 7KC [12]. Knock-down of ORP2 and its ER anchors, the VAP proteins in HuH7 hepatoma cells was found to enhance the hydrolysis and to decrease the synthesis of [<sup>3</sup>H]TGs [50].

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Our recently published observations revealed a cellular role for ORP2 beyond lipid metabolism. Analysis of ORP2 knock-out (ORP2-KO) HuH7 cells indicated a role for ORP2, in addition to lipid metabolism, in actin cytoskeletal regulation as well as in the control of cell adhesion, migration and proliferation [21]. Moreover, analysis of ORP2 protein interactome in HuH7 cells identified ORP2 binding partners involved in RhoA signaling [21], a central actin regulatory pathway. These findings prompted the hypothesis that ORP2 could mediate a crosstalk between lipid metabolism and actin cytoskeletal functions. In the present study we demonstrate a defect in Akt signaling and analyze the energy metabolism and lipidome in HuH7 hepatoma cells subjected to ORP2-KO by CRISPR-Cas9 mediated gene editing.

## Experimental procedures

### Antibodies

The rabbit anti-ORP2 antibody was described in [24]. Anti- $\beta$ -actin was purchased from Sigma–Aldrich (St. Louis, MO). Rabbit anti-Cdc37, anti-Hsp90, anti-Akt, anti-Akt(Ser473), anti-GSK-3 $\beta$  and anti-GSK-3 $\beta$ (Ser9) were from Cell Signaling (Danvers, MA). Mouse monoclonal anti-Cdc37 was from Thermo Scientific (Waltham, MA) and mouse monoclonal anti-cortactin from Merck-Millipore (Temecula, CA). The fluorescent secondary fAlexa Fluor-568 goat anti-rabbit and Cy5<sup>®</sup> goat anti-mouse antibodies were from Molecular Probes/Invitrogen (Carlsbad, CA) and Life Technologies (Eugene, OR), respectively.

### Cell culture, ORP2-KO cell lines, and transfections

The HuH7 human hepatoma cell line [35] was cultured as described in [21, 22]. ORP2-KO lines were derived therefrom by CRISPR-Cas9-mediated gene editing by employing vectors described in [42, 44] as reported in [21]. For the generation of ORP2-KO1 guide RNAs targeting exon 4 of *OSBPL2* were used and for ORP2-KO2 guide RNAs targeting both exon 4 and 5 were used. The Cas9 control HuH7 cells were prepared similarly to the KO cells transfected with the Cas9 expression plasmid without the *OSBPL2*-specific gRNA constructs. HuH7 cells were transfected with a GFP-ORP2 (human ORP2 cDNA in pEGFP-N1, Clontech/TaKaRa Bio, Mountain View, CA) using Lipofectamine<sup>®</sup> 2000 (Invitrogen). Human umbilical vein endothelial cells (HUVECs; Lonza, Basel, Switzerland) were cultured in fibronectin-gelatin coated flasks in endothelial cell growth medium [EGM; 0.1% human epidermal growth factor (EGF), 0.1% hydrocortisone, 0.1% Gentamicin-Amphotericin-B, 0.4% bovine brain extract, 2% foetal bovine serum; Lonza], and transfected by electroporation by using the Nucleofector<sup>®</sup> Kit for HUVECs (Lonza).

### Lentivirus-mediated ORP2 overexpression and knock-down

Generation of recombinant lentiviruses expressing wild-type (wt) ORP2 or its mutants

1  
2  
3  
4 ORP2 mPIP (H178–179A, K423A) and mFFAT (F7–8V, D9V), and a GFP-encoding  
5  
6 vector control, as well as cell infections of ORP2-KO HuH7 cells are described in [21].  
7  
8 Knock-down of ORP2 in HUVECs was carried out by transducing the cells for 48 h at a  
9  
10 multiplicity of infection 10, with an lentivirus expressing the ORP2-specific shRNA,  
11  
12 TRCN0000154381 (Sigma-Aldrich), by using non-targeting SHC002 (Sigma-Aldrich) as  
13  
14 a control. The viruses were packaged and titrated by the Virus Core of the Biomedicum  
15  
16 Functional Genomics Unit (Helsinki Institute of Life Science, HiLIFE).

### 17 18 19 RNA sequencing and pathway analysis

20  
21  
22 RNA sequencing was performed as described in [21]. In detail, samples were prepared  
23  
24 from 4 parallel basal cultures each of ORP2-KO1, ORP2-KO2 and Cas9 control HuH7  
25  
26 cells using TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero (Illumina, San  
27  
28 Diego, CA). BWA [26] was used to align output reads to human reference genome  
29  
30 (GRCh38). The FeatureCounts program [27] was employed to count mapped fragments  
31  
32 against genomic features defined by the Ensembl annotation file  
33  
34 (Homo\_sapiens.GRCh38.76.gtf). The genes with counts equal or less than 1 in all  
35  
36 samples were removed and Deseq2 was used to analyse the differential gene expression  
37  
38 [29]. Benjamini-Hochberg test was used to control the false discovery rate. Genes which  
39  
40 differed significantly (adjusted p-value < 0.05) between ORP2-KO1 and Cas9 control  
41  
42 cells were selected for analysis by Ingenuity Pathways Analysis® tool (IPA,  
43  
44 www.ingenuity.com). Enrichment of the genes in the pathways was assessed in  
45  
46 comparison with a reference set in the whole Ingenuity pathway knowledge base.

### 47 48 49 Western blotting

50  
51  
52 Western blot analyses were carried out as described in [50].

### 53 54 55 Pull-down assay

56  
57  
58 HuH7 cells were grown in basal culture conditions or alternatively treated with 5  $\mu$ M  
59  
60 Withaferin A for 24 h prior to lysis in 10 mM HEPES pH 7.6, 150 mM NaCl, 0.5 mM  
61  
62



1  
2  
3  
4 MgCl<sub>2</sub>, 10 % glycerol, 0.5 % Triton X-100, 0.5 % Na-deoxycholate, Protease inhibitor  
5 cocktail (Roche Diagnostics, Basel, Switzerland). Lysates were mixed thoroughly by  
6 vortexing and incubated on ice for 10 min. Unbroken cells and insoluble material were  
7 removed by 10 min centrifugation at 20,000 x g. The obtained lysates were incubated  
8 with 300 μmol GST-ORP2 or GST [21] and 20 μl Glutathione-Sepharose 4B (GE  
9 Healthcare, Buckinghamshire, UK) for 2 h at 4 °C. The beads were washed four times  
10 with the lysis buffer, resuspended in 30 μl Laemmli sample buffer, boiled for 5 min, and  
11 separated by SDS-PAGE. The bound proteins were detected on western blots with anti-  
12 Cdc37, anti-Akt, and anti-Hsp90 antibodies.

13  
14  
15  
16  
17  
18  
19  
20  
21 To study the role of Akt phosphorylation, cell lysates containing 0.1 mg of total  
22 protein were treated with 2000 U of Lambda protein Phosphatase (λ-PP, New England  
23 BioLabs, Ipswich, MA) in 50 mM HEPES (pH 7.5), 100 mM NaCl, 2 mM DTT, 0.01%  
24 Brij 35, 1 mM MnCl<sub>2</sub> and Protease inhibitor cocktail (Roche Diagnostics) for 1 h at 30°C,  
25 followed by pull-down assay with GST-ORP2 as described above.

### 26 27 28 29 30 31 Immunofluorescence staining

32  
33  
34 HuH7 cells were fixed with 4% paraformaldehyde, 0.02% glutaraldehyde in phosphate  
35 buffered saline (PBS) for 30 min. Aldehyde groups were blocked with 50 mM NH<sub>4</sub>Cl for  
36 15 min and cells were permeabilized with 0.1% Triton X-100 for 5 min. Unspecific  
37 binding of antibodies was blocked with 10% FBS for 45 min, followed by incubation  
38 with the primary antibodies in 5% FBS for 30 min at 37° C. The cells were washed with  
39 PBS, incubated with fluorescent secondary antibodies in 5% FBS for 45 min at 37° C,  
40 and mounted in a mixture of Mowiol (Calbiochem, La Jolla, CA), 1,4-Diazabicyclo-  
41 [2.2.2]octane (50 mg/ml, Sigma-Aldrich), and DAPI (5 μg/ml, Molecular Probes).  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 53 54 Fluorescence microscopy

55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

1  
2  
3  
4  
5  
6 Assays for glucose and fatty acid uptake  
7  
8

9  
10 Glucose uptake was measured in ORP2-KO and Cas9 control cells after starving the cells  
11 in glucose and serum free Dulbecco's modified Eagle medium (DMEM, Gibco, Grand  
12 Island, NY) for 3 h. The cells were treated with a mixture of 10  $\mu$ M 2-Deoxy-D-glucose  
13 (Sigma-Aldrich) and 10  $\mu$ M [ $^3$ H]-2-deoxy-D-glucose (100 mCi/mmol) (PerkinElmer,  
14 Waltham, MA) for 15 min. The non-specific uptake of glucose was measured by treating  
15 the cells 45 min with 40  $\mu$ M Cytochalasin B (Sigma-Aldrich) prior to adding the glucose  
16 mixture. The cells were washed three times with PBS and lysed in 0.03% SDS. The  
17 radioactivity of the lysed cells was measured by liquid scintillation counting in Optiphase  
18 HiSafe 3 scintillation cocktail (PerkinElmer) and normalized to total cellular protein  
19 (BCA assay, Thermo Scientific). The non-specific glucose uptake was subtracted from  
20 the measurements.  
21  
22

23  
24 Fatty acid uptake was measured similarly: ORP2-KO and Cas9 control were  
25 starved in glucose and serum free DMEM for 3 h, followed by treatment with a mixture  
26 of 20 mM glucose, 5 nM oleic acid-BSA and 1  $\mu$ Ci [ $^3$ H]-oleic acid (PerkinElmer) for 15  
27 min. The cell lysis and scintillation counting were performed as described above.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 Assay for glycogen synthesis  
40

41  
42 To measure glycogen synthesis, cells were first starved for 2 h in glucose and serum free  
43 DMEM (Gibco). The cells were then treated with 0.18  $\mu$ Ci/ $\mu$ mol D-[U- $^{14}$ C]-glucose  
44 (PerkinElmer) for 1 h, after which they were washed three times with PBS and lysed in  
45 0.03% SDS. The extracted glycogen was mixed with 1 mg carrier glycogen (Sigma-  
46 Aldrich) and boiled for 30 min, followed by precipitation with 98–99% ethanol. The  
47 precipitated glycogen was washed with 70% ethanol, centrifuged at 20,000 x g for 15 min  
48 and dried from the excess ethanol. The radioactivity of the glycogen was measured with  
49 liquid scintillation counting in Optiphase HiSafe 3 scintillation cocktail (PerkinElmer)  
50 and normalized to total cellular protein (BCA assay, Thermo Scientific).  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 Determination of glycolytic activity  
5  
6

7 To analyze glycolysis, ORP2-KO and Cas9 control cells were seeded on XF96 cell  
8 culture microplates in basal growth medium (Agilent Technologies, Santa Clara, CA).  
9 After 24 h, the culture media was changed to Seahorse XF base medium (Agilent  
10 Technologies) with 2 mM L-glutamine (pH 7.35) and incubated for 1 h at 37°C in a non-  
11 CO<sub>2</sub> incubator. After incubation, extracellular acidification rate (ECAR) was measured in  
12 real time with a Seahorse XFe96 Analyzer (Agilent Technologies) as follows: cells were  
13 treated with 10 mM glucose, 1 μM Oligomycin and 50 mM 2-Deoxy-D-glucose (Sigma-  
14 Aldrich) followed by a 20 min measurement between the treatments. Extracellular  
15 acidification was normalized to total cellular protein. Glycolysis was calculated by  
16 subtracting the non-glycolytic ECAR from the maximum ECAR after glucose injection.  
17  
18  
19  
20  
21  
22  
23  
24  
25

26  
27 Analysis of cellular TG content and TG synthesis  
28

29 Thin-layer chromatography used to analyze the TG content of HuH7 ORP2-KO and Cas9  
30 control cells is described in [16, 22] and the radiometric method to analyze TG synthesis  
31 in [16].  
32  
33  
34  
35  
36  
37  
38

39 Lipidome analysis  
40

41 Methodology of the mass spectrometric lipidome analysis is described in the  
42 Supplementary Materials.  
43  
44  
45  
46  
47

48 Transmission electron microscopy and quantification of LDs and ER–LD contacts  
49

50 For TEM analysis, cells grown on glass coverslips were fixed, osmicated, dehydrated in a  
51 graded ethanol series and acetone, and infiltrated into Epon (TAAB, Aldermaston, United  
52 Kingdom) as described by [41]. 60-nm thick sections were cut parallel to the cover slip,  
53 and post-stained with uranyl acetate and lead citrate. Specimens were observed using Jeol  
54 JEM 1400 (Jeol Ltd., Tokyo, Japan) microscope equipped with Orius SC 1000B bottom  
55 mounted CCD camera (Gatan Inc., USA) at acceleration voltage of 80 kV. For systematic  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 random sampling sixteen cells from each condition were selected at low magnification  
5 and four non-overlapping images were acquired from the cell cytoplasmic area at  
6 nominal magnification of 6000 x. To analyze LDs and ER–LD contact sites, all complete  
7 LDs and the adjacent ER in the TEM micrographs were manually traced using MIB  
8 software [4] and the quantity and the length of ER–LD contacts sites were analyzed using  
9 a custom made plugin in MIB. The probing distance of 150 nm between the ER and LDs  
10 was applied and the profiles closer than 30 nm were assigned as a contact site.  
11  
12  
13  
14  
15  
16  
17

### 18 Statistics

19  
20  
21 In the IPA analysis, Fisher's exact test was used to determine the significance of each  
22 pathway and the Benjamini–Hochberg method was used to control for false discovery  
23 rate. Statistical analysis of TLC data and cell biological assays was carried out by using  
24 Student's T-test (two-tailed, independent).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## Results

### ORP2-KO interferes with Akt signaling

RNA sequencing analysis of HuH7 hepatoma cells subjected to ORP2 knock-out by CRISPR-Cas9 gene editing [21] identified 20 components of the PI3K/Akt signaling pathway dysregulated in the ORP2-KO cells (Fig. 1A,B). Nine of the mRNAs were up-regulated (Fig. 1A, shown in green; Fig. 1B) and 11 down-regulated (Fig. 1A, shown in red; Fig. 1B). Ingenuity<sup>®</sup> pathway analysis of the mRNAs affected by ORP2-KO predicted PI3K/Akt signaling to be significantly inhibited (activation z-score -1.7, p-value of overlapping genes 0.03). Prompted by these observations, the activity of the Akt signaling pathway in the two previously characterized ORP2-KO cell lines (ORP2-KO1 and -2; [21]) and Cas9 control cells was studied by western analysis with phosphor-Akt(Ser473) and glycogen synthase kinase 3 $\beta$  [GSK-3 $\beta$ (Ser9)] antibodies. The cells were either serum starved for 2 h (Fig. 1A) or grown in the basal culture medium (Fig. 1B), in the absence or presence of 8 min stimulation with 100 nM insulin, prior to lysis and sample preparation. The levels of Akt(Ser473) or GSK-3 $\beta$ (Ser9) were normalized to the total Akt and GSK-3 $\beta$  signals. The analysis revealed significant inhibition in the phosphorylation of Akt (Fig. 2C) and GSK-3 $\beta$  (Fig. 2D), under both basal and insulin-stimulated conditions [by 35–73% and 30–36%, respectively], indicating a suppression of PI3K/Akt signaling in the ORP2-KO cells.

To confirm the effect of ORP2 depletion on Akt(Ser473) phosphorylation also in non-cancerous cells, we subjected primary human umbilical vein endothelial cells (HUVECs) to ORP2 knock-down with a lentivirus expressing ORP2-specific shRNA. In these cells, a similar dampening of Akt activation (-65%) upon epidermal growth factor (EGF) stimulation as in the HuH7 model, was observed (Fig. 2E). Furthermore, to assess whether the Akt phosphorylation defect is directly caused by the lack of ORP2, we overexpressed wild type (wt) ORP2 or its mutants defective in binding the ER receptors, VAPs (mFFAT), or phosphoinositides (mPIP) in the basally cultured HUVECs with a lentiviral vector, followed by western analysis of Akt(Ser473) phosphorylation. In these experiments the wt ORP2 but also both of the mutants were capable of enhancing the phosphorylation of Akt. The effect of ORP2(mFFAT) was weaker than of the wt and

1  
2  
3  
4 mPIP proteins, but this may be due to the lower expression level (or reduced stability) of  
5  
6 the mFFAT protein (Supplemental Fig. S1A).  
7  
8  
9

10  
11 ORP2 interacts with the Akt effectors Cdc37 and Hsp90  
12  
13

14 We previously identified the ORP2 interactome in HuH7 cells by a co-  
15 immunoprecipitation approach [21]. Interestingly, the Akt effector heat shock protein 90  
16 (Hsp90) co-chaperone Cdc37 was identified in this analysis as a specific partner of ORP2.  
17 We now validated the interaction of ORP2 with endogenous Cdc37 by pull-down assays  
18 using recombinant GST-ORP2 and lysates of HuH7 cells. The GST-ORP2 pull-downs  
19 contained abundant Cdc37, while the negative controls with plain GST lacked the signal  
20 (Fig. 2F), supporting a specific interaction of Cdc37 with ORP2. To clarify whether  
21 ORP2 is physically associated with the Akt signaling activating protein complex Hsp90–  
22 Cdc37–Akt, the pull-down fractions were probed with anti-Akt and anti-Hsp90  
23 antibodies. Interestingly, the analysis revealed specific signals in the GST-ORP2 pull-  
24 downs for both Akt and Hsp90 (Fig. 2F), suggesting that ORP2 may interact with the  
25 Hsp90–Cdc37–Akt complex. Of note, the ORP2 interactome [21] contained, in addition  
26 to Cdc37, also other established Hsp90-associated proteins: FK506-binding protein 4  
27 (FKBP52) [38] and nuclear autoantigen sperm protein (NASP) [1].  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

41 To further analyze the specificity of ORP2 interaction with the Hsp90–Cdc37–  
42 Akt complex, cells were treated with 5  $\mu$ M Withaferin A for 24 h prior to the pull down  
43 assays. Withaferin A is a steroidal lactone which has previously been shown to bind  
44 Hsp90, inhibiting its interaction with Cdc37 and hence its chaperone activity. Thereby,  
45 this drug reduces the phosphorylation and enhances the degradation of Akt [55]. In our  
46 pull-down assays the Withaferin A treatment did not disrupt the interaction of ORP2 with  
47 Hsp90 or Cdc37 (Fig. 2G), bringing up the possibility that ORP2 may interact directly  
48 with both of these proteins. The Withaferin A treatment did, however, drastically reduce  
49 the phosphorylation of Akt, evident from an Akt mobility shift. We confirmed that this  
50 shift truly reflects loss of Akt phosphorylation by dephosphorylation of Akt with lambda  
51 protein phosphatase before the SDS-PAGE/western analysis (Fig. 2H). Moreover, GST-  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 ORP2 was only able to pull down the lower mobility, hyperphosphorylated active form of  
5 Akt and the interaction was abolished upon dephosphorylation with lambda phosphatase  
6 (Fig. 2H), supporting a functional role of ORP2 in the protein complex that promotes Akt  
7 activation.  
8  
9  
10  
11  
12  
13

14 ORP2 colocalizes with Cdc37 and phosphorylated Akt at lamellipodia

15  
16  
17 To visualize the distribution of ORP2, Cdc37 and active Akt, cells transfected with  
18 ORP2-GFP were after insulin stimulation stained for the endogenous Cdc37 and  
19 Akt(Ser473) (Supplemental Fig. S2). Since HuH7 cells are not particularly amenable to  
20 morphologic observation, these studies were also carried out in HUVECs (Fig. 3).  
21 Interestingly, ORP2 was found to co-localize with both Cdc37 and Akt(Ser473) at  
22 specific regions of the cell surface, which were by cortactin staining shown to represent  
23 actively expanding lamellipodia (Fig. 3A,B; Supplemental Fig. S2). Of note, we recently  
24 showed that a defect in lamellipodia formation is a hallmark phenotype of the ORP2-KO  
25 cells, resulting in decreased cell motility [21]. We have previously reported prominent  
26 localization of ORP2 at the surface of cytoplasmic lipid droplets or at ER domains that  
27 associate with LD surfaces [16, 22, 50]. The lamellipodial localization is easily  
28 overlooked in cells that display intense ORP2 staining at the LD. Moreover, in cells  
29 treated with the high-affinity oxysterol ligand of ORP2, 22(R)hydroxycholesterol [16, 22],  
30 or in ones that do not have large LDs, the emphasis of ORP2 localization is frequently  
31 seen at the cell cortex. To analyse whether the lamellipodial localization is dependent of  
32 interaction of ORP2 with VAPs, an ORP2 mutant incapable of VAP-binding (mFFAT)  
33 was overexpressed in HUVECs and the lamellipodia were visualized with cortactin  
34 staining. Similar to wt ORP2, the ORP2(mFFAT) co-localized with cortactin at  
35 lamellipodial cell surface protrusions, indicating that the interaction of ORP2 with the ER  
36 is not essential for its lamellipodial localization (Fig. 3C).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 ORP2 knock-out reduces glucose uptake and glycogen synthesis  
5  
6

7 The Akt serine/threonine kinase plays a key role in the regulation of glucose homeostasis  
8 by elevating glucose uptake and increasing glycogen synthesis via phosphorylation of  
9 GSK-3 [9]. The results outlined in 3.1. demonstrated that the loss of ORP2 suppresses  
10 Akt signaling with possible effects on cellular carbohydrate metabolism. In addition, the  
11 ORP2-KO cells' transcriptome and IPA analyses indicated a close link between ORP2  
12 and carbohydrate metabolism (p-value of overlapping genes 0.018). Therefore, the  
13 capacity of ORP2-KO cells to take up glucose was measured by incubating glucose- and  
14 serum-starved cells with [<sup>3</sup>H]-2-deoxy-D-glucose for 15 min, followed by measurement  
15 of the cellular radioactivity. The analysis demonstrated that the glucose uptake was  
16 reduced by 28–33% in the ORP2-KO cells as compared to the controls (Fig. 4A).  
17  
18  
19  
20  
21  
22  
23  
24

25 To further characterize the intracellular handling of glucose, the incorporation of  
26 D-[U-<sup>14</sup>C]-glucose into glycogen during 1 h was analyzed in ORP2-KO and control cells.  
27 The synthesis of glycogen in ORP2-KO cells was reduced by 50–58 % as compared to  
28 the control (Fig. 4B), fully consistent with the observed reduction of GSK-3β(Ser9)  
29 phosphorylation. We next re-expressed ORP2 in the KO cells by using a lentiviral vector  
30 to determine if this can rescue the defect in glycogen synthesis. The expression of ORP2  
31 elevated glycogen synthesis in these cells by 37% as compared to the mock-transfected  
32 KO control (Fig. 4C), confirming that the synthesis defect is truly due to the loss of  
33 ORP2. In order to study whether the interactions of ORP2 with VAPs or  
34 phosphoinositides are necessary for this rescue effect, we also re-expressed the mFFAT  
35 and mPIP mutants of ORP2 in the KO cells, followed by analyses of glycogen synthesis.  
36 The results revealed that ORP2(mFFAT) rescued the glycogen synthesis, whereas the  
37 effect of ORP2(mPIP) varied between experiments, with no statistically significant  
38 overall rescue effect detectable (Supplemental Fig. S1B). These observations suggest that  
39 the binding of VAPs may be dispensable for the function of ORP2 in glucose metabolism,  
40 while the functional significance of PIP binding cannot be reliably inferred from the  
41 present data.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



## ORP2-KO inhibits glycolysis

The RNA sequencing demonstrated that the loss of ORP2 results in down-regulation of 12 major glycolytic genes, glycolysis being indicated as a significantly affected function by the IPA analysis of the ORP2-KO cells (p-value of overlapping genes 0.003; Fig. 4D,E). The glycolytic capacity of ORP2-KO and control cells was therefore measured with a Seahorse<sup>®</sup> XFe96 extracellular flux analyser by monitoring their extracellular acidification rate in the presence of glucose substrate (Fig. 4F). Consistent with the suppression of major glycolytic genes, the rate of glycolysis was in the ORP2-KO cells reduced by 22–37% as compared to the controls (Fig. 4G).

## Knock-out of ORP2 reduces the cellular triacylglycerol content

Prompted by our earlier observations on impacts of ORP2 knock-down on cellular TG metabolism [16, 50], we investigated the TG content of ORP2-KO and Cas9 control cells under basal culture conditions by thin-layer chromatography. The analysis revealed a significant, 21–28% reduction of the cellular TGs in the ORP2-KO cells as compared to the controls (Fig. 5A). The capacity of ORP2-KO and control cells to synthesize TGs was measured by [<sup>3</sup>H]-oleic acid labeling during a 3 h period. TG synthesis by the KO cells was reduced by 41–53 % as compared to the controls (Fig. 5B). Of note, fatty acid uptake measured by incubating the cells with [<sup>3</sup>H]-palmitic acid did not differ between the ORP2-KO and the controls (Fig. 5C), consistent with a defect in the activation or incorporation of fatty acids into TGs. We next re-expressed ORP2 in the KO cells with a lentiviral vector and measured the effect on TG synthesis as above. The re-expression of ORP2 increased the TG synthesis by 31 % as compared to the mock-transfected KO control (Fig. 5D), demonstrating that the TG synthesis defect results from the loss of ORP2. However, no significant difference between the TG synthesis rescue with the wt ORP2 and ORP2 mutants mFFAT and mPIP was detected (Supplemental Fig. S1C), suggesting that the ORP2 TG metabolic function is not directly dependent on ORP2's ability to bind VAP or PIPs.

1  
2  
3  
4  
5  
6  
7 ORP2 knock-out modulates the expression of SREBP-1 and TG metabolic genes  
8  
9

10 The cellular TGs are retained within intracellular lipid droplets (LD), which store energy  
11 in the form of neutral lipids. The balance between TG synthesis and hydrolysis is  
12 coordinated to respond to the fluctuating energy demands of the cell. One master  
13 regulator of TG homeostasis is the transcription factor Sterol regulatory element-binding  
14 protein-1, SREBP-1 [14]. To obtain clues of the mechanisms underlying the phenotypic  
15 effects of ORP2-KO, we again analyzed the transcriptome data of these cells [21].  
16  
17

18  
19  
20 When the mRNAs dysregulated in the ORP2-KO cells were compared to known  
21 SREBP-1 target genes [43], 27 established SREBP-1 targets were found to be  
22 significantly affected by the ORP2-KO (Fig. 5E). Moreover, we compared the mRNAs  
23 affected by ORP2-KO with the list of gene promoters occupied by SREBP-1 in a global  
24 chromatin immunoprecipitation analysis [43]. This comparison revealed 168 genes the  
25 promoters of which are occupied by SREBP-1 and which are affected by the loss of  
26 ORP2 (Supplemental Table S1). IPA analysis of the mRNAs affected by ORP2-KO  
27 predicted SREBP-1 transcriptional regulation to be significantly inhibited (activation z-  
28 score -2.2, p-value of overlapping genes 0.0001). This suggests that the observed  
29 reduction in the TG content of ORP2-KO cells is at least in part due to a suppression of  
30 SREBP-1 function. In addition to the SREBP-1 targets, we identified among the genes  
31 affected by ORP2-KO 11 other mRNAs with established roles in TG metabolism (Fig.  
32 5F). The above results imply that the depletion of cellular TGs by ORP2-KO involves  
33 disturbed transcriptional regulation of multiple TG homeostatic genes.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 ORP2-KO does not reduce the quantity of ER-LD contacts but alters their dynamics  
49 upon fatty acyl loading  
50  
51

52 ORP2 was previously found to localize on the surface of intracellular LDs or at ER-LD  
53 membrane contact sites [16, 22]. To investigate whether the loss of ORP2 affects the  
54 extent of ER-LD contacts, we analyzed by TEM the ORP2-KO cell lines and Cas9  
55 control cells grown under basal conditions or after 3 h fatty acid loading (Fig. 6A). Upon  
56 fatty acid loading, the total LD area increased significantly in Cas9 control and ORP2-  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 KO1, the increase being minor and insignificant in ORP2-KO2 (Fig. 6B). However, the  
5 total length of ER–LD contacts was only significantly increased in Cas9 control cells  
6 upon FA loading, but did not change in ORP2-KO cells. Of note, the length of ER–LD  
7 contacts was significantly elevated in ORP2-KO cells under basal conditions compared to  
8 Cas9 controls (Fig. 6C). These observations demonstrated that ORP2 is not essential for  
9 the formation of ER–LD contacts nor the growth of LD upon FA loading, but may  
10 modulate the dynamic expansion of the ER–LD contacts under conditions in which TGs  
11 are actively synthesized.  
12  
13  
14  
15  
16  
17  
18

19 Based on the RNA sequencing analysis, we found no evidence that ORP2-KO  
20 would affect the expression of the previously identified LD–ER tethering factors such as  
21 Insulin-sensitive fatty acid transport protein 1 (FATP1/SLC25A1) [53], diacylglycerol O-  
22 acyltransferase 2 (DGAT2) [53], Seipin/BSCL2 [44] or Monoacylglycerol  
23 acyltransferase 1 (MGAT1) [25]. The RNA sequencing analysis did, however, reveal that  
24 ORP2-KO results in the suppression of mRNAs encoding components important for LD  
25 formation or growth: Perilipin 2 (-28%; adjusted p=6.05E-16) [5] and glycerol-3-  
26 phosphate acyltransferase 4 (GPAT4; -13%; adjusted p=5.8E-5) [51].  
27  
28  
29  
30  
31  
32  
33  
34

35 Knock-out of ORP2 has no significant impact on the quantities of major membrane  
36 phospholipids and sterols  
37  
38

39 Previous research suggests a functional role of ORP2 in cellular neutral lipid and sterol  
40 homeostasis [12, 15, 16, 24]. These studies were performed by employing ORP2  
41 overexpression or partial knock-down. Here we analysed lipid classes and their molecular  
42 species in HuH7 cells with a complete knock-out of ORP2, grown in serum-containing  
43 basal medium. Of note, the mass spectrometry platform did not cover TGs, which were  
44 analyzed by TLC. In addition, the cellular sterol content was manipulated by lipoprotein  
45 starvation, Mevastatin or LDL treatments.  
46  
47  
48  
49  
50  
51

52 We first analyzed ORP2-KO and control hepatocytes' content of  
53 glycerophospholipids [phosphatidylcholines (PCs), lyso-PCs (LPCs),  
54 phosphatidylethanolamines (PEs), PE-plasmalogens (PE-Ps), phosphatidylinositols (PIs),  
55 -serines (PSs), and -glycerols (PGs)], ceramides, sphingomyelin, free (FC) and esterified  
56 cholesterol (CEs), as well as five oxysterols (25OHC, 27OHC, 7 $\alpha$ OHC, 7 $\beta$ OHC and  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 7KC). The analysis did not reveal significant alterations in any of the analyzed lipid  
5  
6 classes nor the oxysterol species in the ORP2-KO cells as compared to the controls  
7  
8 (Supplemental Fig. S3A). Neither did the cellular sterol manipulations reveal possible  
9  
10 latent effects on the cellular concentrations of FC or CEs, which might have remained  
11  
12 undetected under the basal conditions (Supplemental Fig. S3B). Moreover, clustering  
13  
14 analysis grouped the molecular species into nine distinct lipid clusters, none of which  
15  
16 differed significantly between ORP2-KO and Cas9 cells. However, RNA sequencing of  
17  
18 the ORP2-KO cells revealed significant alterations in the mRNA expression of 11  
19  
20 established cholesterol homeostatic genes (Supplemental Table S2), bringing up the  
21  
22 possibility that the cells chronically devoid of ORP2 may have adapted to a putative  
23  
24 disturbance of cholesterol homeostasis via transcriptional changes. Upon analysis of  
25  
26 individual lipid molecular species, very few differences were detectable between the  
27  
28 ORP2-KO and control cells, and none of these remained significant after multiple test  
29  
30 correction (Supplemental Table S3).  
31  
32

## 33 **Discussion**

34  
35  
36 We employ in this study a complete CRISPR-Cas9 knock-out of ORP2 HuH7 cells to  
37  
38 comprehensively analyse the impacts of the loss of ORP2 function. The knock-out  
39  
40 resulted in reductions of Akt activity, glucose uptake, glycogen synthesis, glycolysis,  
41  
42 mRNAs encoding glycolytic enzymes and SREBP-1 target genes, as well as defective TG  
43  
44 synthesis and storage. The defect in Akt activity was observed in both the ORP2-KO  
45  
46 HuH7 hepatoma cells and in primary endothelial cells subjected to ORP2 knock-down.  
47  
48 ORP2 was found to form a physical complex with key controllers of Akt activity, Cdc37  
49  
50 and Hsp90, and to co-localize with Cdc37 and active Akt(Ser473) at the lamellipodia of  
51  
52 both HuH7 cells and the non-cancerous HUVECs. Of note, although ORP2-VAPA  
53  
54 complexes are reported to localize at ER-LD contacts [50], our quantitative EM analysis  
55  
56 demonstrated that loss of ORP2 did not abolish or reduce the ER-LD membrane contact  
57  
58 sites; Under the basal culture conditions even a modest increase of the total length and  
59  
60 number of such contacts was observed in the KO cells. Interestingly, these parameters  
61  
62 increased significantly in the Cas9 controls upon fatty acid loading, while no significant  
63  
64  
65

1  
2  
3  
4 increase occurred in the KO-cells, suggesting a functional role of ORP2 or its interaction  
5 partners in the dynamic regulation of ER–LD contacts. The knock-out did not  
6 significantly affect the cellular levels of membrane phospholipids, cholesterol or  
7 oxysterols.  
8  
9

10  
11 In the present study, the discovery of ORP2 function in Akt signaling is of central  
12 importance. Our results show that ORP2 is physically associated with an Akt activation  
13 complex that contains Cdc37 and Hsp90 [3, 45]. Moreover, we demonstrate that GST-  
14 ORP2 selectively pulls down the active, hyperphosphorylated form of Akt, and that the  
15 loss of ORP2 inhibits Akt signaling, consistent with the notion that ORP2 plays an  
16 important role in Akt activation. In this context one should also consider our earlier  
17 observation that ORP2 interacts *in vitro* with vesicles containing phosphoinositides,  
18 particularly PI(3,4,5)P<sub>3</sub> [15], which plays a key role Akt activation, and with IQGAP1  
19 [21], which is suggested to play an important role in PI(3,4,5)P<sub>3</sub> formation by scaffolding  
20 phosphoinositide kinases as well as PDK1 and Akt into functional proximity [7].  
21 Importantly, our results demonstrate that ORP2-KO inhibits glucose uptake, glycogen  
22 synthesis, and glycolysis, effects that most likely result from the suppression of Akt  
23 signaling in the KO cells. Akt signaling regulates glucose uptake into hepatocytes by  
24 increasing the expression and plasma membrane localization of GLUT1 [2, 23], the  
25 mRNA of which was significantly suppressed in the ORP2-KO cells (by 30%; adjusted  
26 p-value 3.3E-18). Akt also regulates glucose uptake indirectly by promoting a  
27 concentration gradient: It induces the expression of glucokinase [18], which reduces the  
28 intracellular glucose concentration by phosphorylation of glucose. Thus, we envision that  
29 the observed impairment of glucose uptake in the ORP2-KO cells is at least in part  
30 explained by the suppression of Akt signaling. Moreover, by fold-change the most up-  
31 regulated individual mRNA in ORP2-KO cells was Thioredoxin-interacting protein [21],  
32 which suppresses the function of GLUT1 [52].  
33  
34

35 Inhibition of glycogen synthesis observed in the ORP2-KO cells is consistent with  
36 the reduced Akt-mediated phosphorylation of GSK-3. Glycogen synthase is regulated by  
37 reversible phosphorylation by GSK-3, which itself is phosphorylated and inactivated by  
38 Akt [9]. Importantly, activation of Akt promotes the conversion of cellular energy  
39 metabolism from oxidative phosphorylation to glycolysis by increasing the expression of  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 glycolytic enzymes [46]. Consistently, the reduction of active Akt in the ORP2-KO cells  
5 coincided in the present study with a down-regulation of the mRNAs encoding all major  
6 glycolytic enzymes and glycolysis measured as ECAR. Rescue of glycogen synthesis in  
7 the ORP2-KO cells by ORP2(mFFAT) suggested that, at least under the overexpression  
8 conditions, linking to the ER via VAPs is not required for the function of ORP2 in  
9 glucose metabolism. Consistently, the mFFAT mutant defective in VAP binding  
10 localized, similar to the wt ORP2, to the cell cortex where key regulation of Akt activity  
11 takes place (see below), and its overexpression enhanced Akt phosphorylation at Ser473.  
12 Similar to mFFAT, the PIP binding deficient mutant ORP2(mPIP) did enhance Akt  
13 phosphorylation, suggesting that PIP binding by ORP2 is not absolutely necessary for its  
14 function in the regulation of Akt, even though we could not obtain conclusive results on  
15 the ability of this mutant to rescue glycogen synthesis in the KO cells.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 Our latest work suggested an important role of ORP2 in actin-dependent cell  
27 adhesion and migration [21], processes tightly connected with glycolysis: Glycolytic  
28 enzymes such as GAPDH and aldolase associate with F-actin, and the acute energy  
29 requirements in motile cell protrusions and filopodia are met by rapid local ATP  
30 synthesis via glycolysis [10, 33, 36]. On the other hand, PI(3,4,5)P<sub>3</sub> and Akt orchestrate  
31 lamellipodia formation and cell migration by inducing actin polymerization at the leading  
32 edge of cells. PI(3,4,5)P<sub>3</sub> and active Akt are found localizing in lamellipodia, and  
33 PI3K/Akt inhibitors disrupt lamellipodia formation and reduce cell motility [6, 20, 49].  
34 Here we show that ORP2 co-localizes with active Akt(Ser473) and Cdc37 at cortactin-  
35 positive lamellipodia, in agreement with a functional interplay of these proteins in cell  
36 migration. Consistently, we recently demonstrated that the ORP2-KO cells are defective  
37 in lamellipodia formation and migration [21]. Thus, the present observations suggest a  
38 new, ORP-mediated regulatory link between cellular energy metabolism and motility.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 How does the major lipid phenotype of the ORP2-KO cells, the reduction of TGs,  
51 relate to the defective glucose metabolism and Akt signaling? Obviously, reduced  
52 glucose uptake and glycolysis are likely to be reflected in a reduced supply of precursors  
53 for *de novo* lipogenesis via the tricarboxylic acid cycle. However, the defective Akt  
54 signaling may contribute to the reduction of TG synthesis and storage also via another  
55 mechanism. Akt plays an important role in hepatic lipogenesis by enhancing transcription  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 and nuclear localization of the lipogenic transcription factor SREBP-1c [13, 39, 40, 54].  
5  
6 Thus, we envision that the present TG and glucose phenotypes may arise as a combined  
7  
8 effect of Akt and SREBP-1 defects, and the Akt defect may be one factor contributing to  
9  
10 the disturbance of SREBP-1 target gene expression. A model of ORP2 function in Akt  
11  
12 signaling arising from the present results is presented in Fig. 7.

13  
14 ORP2 was previously implicated in TG metabolism at ER-LD contacts [50],  
15  
16 cholesterol transport [15, 19, 24], adrenocortical steroidogenesis [12], and actin-  
17  
18 dependent cell dynamics [21]. The present analysis is consistent with a function of the  
19  
20 protein as a regulator TG synthesis and storage. Rescue of the TG synthesis defect by  
21  
22 ORP2(mFFAT) and ORP2(mPIP) suggests that, at least under the overexpression  
23  
24 conditions, the interactions with VAPs and PIPs are not necessary for the function of  
25  
26 ORP2 in TG metabolism. The reported activities of ORP2 in cellular cholesterol  
27  
28 homeostasis are not directly supported by the present data. We have previously shown  
29  
30 that the loss of ORP2 does not cause significant compensatory changes in the mRNA  
31  
32 levels of the 10 other ORPs expressed in HuH7 cells or their ER receptors, the VAMP-  
33  
34 associated proteins A and B [21]. However, the present RNA sequencing analysis  
35  
36 suggests that putative distortions of cholesterol homeostasis caused by the chronic loss of  
37  
38 ORP2 may have been compensated for by altered mRNA expression of a number of  
39  
40 cholesterol homeostatic genes.

41  
42 To conclude, the present study, together with our recently published work,  
43  
44 identifies ORP2 as a new regulatory nexus of Akt signaling, cellular energy metabolism,  
45  
46 actin cytoskeletal function, cell migration and proliferation.

## 47 **Conflict of interest**

48  
49  
50 The authors declare no conflict of interest.

## 51 **Acknowledgments**

52  
53  
54 We thank Riikka Kosonen and Mervi Lindman for expert technical assistance and Adj.  
55  
56 prof. Reijo Käkelä (Department of Biosciences, University of Helsinki) for valuable  
57  
58 comments on the manuscript. Personnel of the Genome Biology Unit (Biocenter Finland)  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 and the Biomedicum Functional Genomics Unit (Helsinki Institute of Life Science,  
5 HiLIFE) are acknowledged for help in generating the recombinant lentiviruses. Prof.  
6  
7 Feng Zhang (Broad Institute of Massachusetts Institute of Technology and Harvard,  
8 Cambridge, MA) is thanked for kindly providing components of the CRISPR-Cas9 vector  
9 system.  
10  
11  
12

## 13 14 **Funding**

15  
16  
17 This study was supported by grants from the Academy of Finland (285223 to V.M.O.,  
18 307415 and 312491 to E.I.), the University of Helsinki Doctoral Programme in  
19 Biomedicine (H.K.), the Finnish Concordia Fund (H.K.), the Ida Montin Foundation  
20 (H.K.), the Finnish-Norwegian Medical Foundation (H.K.), the Aarne Koskelo  
21 Foundation (H.K.), the Orion Research Foundation sr (H.K.), the Päivikki and Sakari  
22 Sohlberg Foundation (H.K.), the Sigrid Juselius Foundation, the Magnus Ehrnrooth  
23 Foundation, and the Finnish Foundation for Cardiovascular Research (V.M.O.). Electron  
24 Microscopy Unit is supported by Biocenter Finland and Helsinki Institute of Life Science.  
25 The funding bodies played no role in the study design, analysis or interpretation of the  
26 data, writing of the report or the decision to submit the article for publication.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4 **References**  
5  
6

- 7 1. Alekseev OM, Widgren EE, Richardson RT and O'Rand MG (2005) Association of  
8 NASP with HSP90 in mouse spermatogenic cells: stimulation of ATPase activity and  
9 transport of linker histones into nuclei. *J Biol Chem* 280:2904-2911.  
10  
11  
12  
13 2. Barthel A, Okino ST, Liao J, Nakatani K, Li J, Whitlock JP, Jr and Roth RA (1999)  
14 Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. *J Biol*  
15 *Chem* 274:20281-20286  
16  
17  
18  
19 3. Basso AD, Solit DB, Chiosis G, Giri B, Tsiichlis P and Rosen N (2002) Akt forms an  
20 intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized  
21 by inhibitors of Hsp90 function. *J Biol Chem* 277:39858-39866.  
22  
23  
24  
25  
26 4. Belevich I, Joensuu M, Kumar D, Vihinen H and Jokitalo E (2016) Microscopy Image  
27 Browser: A Platform for Segmentation and Analysis of Multidimensional Datasets. *PLoS*  
28 *Biol* 14:e1002340. doi: 10.1371/journal.pbio.1002340  
29  
30  
31  
32 5. Bickel PE, Tansey JT and Welte MA (2009) PAT proteins, an ancient family of lipid  
33 droplet proteins that regulate cellular lipid stores. *Biochim Biophys Acta* 1791:419-440.  
34  
35  
36  
37 6. Chanvorachote P, Chunhacha P and Pongrakhananon V (2014) Caveolin-1 induces  
38 lamellipodia formation via an Akt-dependent pathway. *Cancer Cell Int* 14:52-2867-14-52.  
39  
40  
41  
42 7. Choi S, Hedman AC, Sayedyahosseini S, Thapa N, Sacks DB and Anderson RA  
43 (2016) Agonist-stimulated phosphatidylinositol-3,4,5-trisphosphate generation by  
44 scaffolded phosphoinositide kinases. *Nat Cell Biol* 18:1324-1335.  
45  
46  
47  
48 8. Chung J, Torta F, Masai K, Lucast L, Czaplá H, Tanner LB, Narayanaswamy P, Wenk  
49 MR, Nakatsu F and De Camilli P (2015) INTRACELLULAR TRANSPORT.  
50 PI4P/phosphatidylserine countertransport at ORP5- and ORP8-mediated ER-plasma  
51 membrane contacts. *Science* 349:428-432.  
52  
53  
54  
55  
56 9. Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA (1995) Inhibition  
57 of glycogen synthase kinase-3 by insulin mediated by protein kinase B. *Nature* 378:785-  
58 789.  
59  
60  
61  
62

- 1  
2  
3  
4 10. De Bock K, Georgiadou M and Carmeliet P (2013) Role of endothelial cell  
5 metabolism in vessel sprouting. *Cell Metab* 18:634-647.  
6  
7  
8  
9 11. de Saint-Jean M, Delfosse V, Douguet D, Chicanne G, Payrastre B, Bourguet W,  
10 Antonny B and Drin G (2011) Osh4p exchanges sterols for phosphatidylinositol 4-  
11 phosphate between lipid bilayers. *J Cell Biol* 195:965-978.  
12  
13  
14 12. Escajadillo T, Wang H, Li L, Li D and Sewer MB (2016) Oxysterol-related-binding-  
15 protein related Protein-2 (ORP2) regulates cortisol biosynthesis and cholesterol  
16 homeostasis. *Mol Cell Endocrinol* 427:73-85.  
17  
18  
19 13. Fleischmann M and Iynedjian PB (2000) Regulation of sterol regulatory-element  
20 binding protein 1 gene expression in liver: role of insulin and protein kinase B/cAkt.  
21 *Biochem J* 349:13-17  
22  
23  
24 14. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS and  
25 Goldstein JL (2003) Combined analysis of oligonucleotide microarray data from  
26 transgenic and knockout mice identifies direct SREBP target genes. *Proc Natl Acad Sci U*  
27 *S A* 100:12027-12032.  
28  
29  
30 15. Hynynen R, Laitinen S, Käkälä R, Tanhuanpää K, Lusa S, Ehnholm C, Somerharju P,  
31 Ikonen E and Olkkonen VM (2005) Overexpression of OSBP-related protein 2 (ORP2)  
32 induces changes in cellular cholesterol metabolism and enhances endocytosis. *Biochem J*  
33 390:273-283.  
34  
35  
36 16. Hynynen R, Suchanek M, Spandl J, Back N, Thiele C and Olkkonen VM (2009)  
37 OSBP-related protein 2 is a sterol receptor on lipid droplets that regulates the metabolism  
38 of neutral lipids. *J Lipid Res* 50:1305-1315.  
39  
40  
41 17. Im YJ, Raychaudhuri S, Prinz WA and Hurley JH (2005) Structural mechanism for  
42 sterol sensing and transport by OSBP-related proteins. *Nature* 437:154-158.  
43  
44  
45 18. Iynedjian PB (2009) Molecular physiology of mammalian glucokinase. *Cell Mol*  
46 *Life Sci* 66:27-42.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 19. Jansen M, Ohsaki Y, Rita Rega L, Bittman R, Olkkonen VM and Ikonen E (2011)  
5 Role of ORPs in sterol transport from plasma membrane to ER and lipid droplets in  
6 mammalian cells. *Traffic* 12:218-231.  
7  
8  
9  
10  
11 20. Kakinuma N, Roy BC, Zhu Y, Wang Y and Kiyama R (2008) Kank regulates RhoA-  
12 dependent formation of actin stress fibers and cell migration via 14-3-3 in PI3K-Akt  
13 signaling. *J Cell Biol* 181:537-549.  
14  
15  
16  
17 21. Kentala H, Koponen A, Kivelä AM, Andrews R, Li C, Zhou Y and Olkkonen VM  
18 (2018) Analysis of ORP2-knockout hepatocytes uncovers a novel function in actin  
19 cytoskeletal regulation. *FASEB J* 32:1281-1295.  
20  
21  
22  
23 22. Kentala H, Pfisterer SG, Olkkonen VM and Weber-Boyvatt M (2015) Sterol  
24 liganding of OSBP-related proteins (ORPs) regulates the subcellular distribution of ORP-  
25 VAPA complexes and their impacts on organelle structure. *Steroids* 99:248-258.  
26  
27  
28  
29 23. Kohn AD, Summers SA, Birnbaum MJ and Roth RA (1996) Expression of a  
30 constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake  
31 and glucose transporter 4 translocation. *J Biol Chem* 271:31372-31378  
32  
33  
34  
35 24. Laitinen S, Lehto M, Lehtonen S, Hyvärinen K, Heino S, Lehtonen E, Ehnholm C,  
36 Ikonen E and Olkkonen VM (2002) ORP2, a homolog of oxysterol binding protein,  
37 regulates cellular cholesterol metabolism. *J Lipid Res* 43:245-255  
38  
39  
40  
41  
42 25. Lee YJ and Kim JW (2017) Monoacylglycerol O-acyltransferase 1 (MGAT1)  
43 localizes to the ER and lipid droplets promoting triacylglycerol synthesis. *BMB Rep*  
44 *50:367-372.*  
45  
46  
47  
48 26. Li H and Durbin R (2009) Fast and accurate short read alignment with Burrows-  
49 Wheeler transform. *Bioinformatics* 25:1754-1760.  
50  
51  
52  
53 27. Liao Y, Smyth GK and Shi W (2014) featureCounts: an efficient general purpose  
54 program for assigning sequence reads to genomic features. *Bioinformatics* 30:923-930.  
55  
56  
57  
58 28. Loewen CJ, Roy A and Levine TP (2003) A conserved ER targeting motif in three  
59 families of lipid binding proteins and in Opi1p binds VAP. *EMBO J* 22:2025-2035.  
60  
61  
62

- 1  
2  
3  
4 29. Love MI, Huber W and Anders S (2014) Moderated estimation of fold change and  
5 dispersion for RNA-seq data with DESeq2. *Genome Biol* 15:550.  
6  
7  
8  
9 30. Maeda K, Anand K, Chiapparino A, Kumar A, Poletto M, Kaksonen M and Gavin  
10 AC (2013) Interactome map uncovers phosphatidylserine transport by oxysterol-binding  
11 proteins. *Nature* 501:257-261.  
12  
13  
14  
15 31. Mesmin B, Bigay J, Moser von Filseck J, Lacas-Gervais S, Drin G and Antonny B  
16 (2013) A four-step cycle driven by PI(4)P hydrolysis directs sterol/PI(4)P exchange by  
17 the ER-Golgi tether OSBP. *Cell* 155:830-843.  
18  
19  
20  
21 32. Mesmin B, Bigay J, Polidori J, Jamecna D, Lacas-Gervais S and Antonny B (2017)  
22 Sterol transfer, PI4P consumption, and control of membrane lipid order by endogenous  
23 OSBP. *EMBO J*. doi: e201796687 [pii]  
24  
25  
26  
27 33. Minaschek G, Groschel-Stewart U, Blum S and Bereiter-Hahn J (1992)  
28 Microcompartmentation of glycolytic enzymes in cultured cells. *Eur J Cell Biol* 58:418-  
29 428  
30  
31  
32  
33  
34 34. Moser von Filseck J, Copic A, Delfosse V, Vanni S, Jackson CL, Bourguet W and  
35 Drin G (2015) INTRACELLULAR TRANSPORT. Phosphatidylserine transport by  
36 ORP/Osh proteins is driven by phosphatidylinositol 4-phosphate. *Science* 349:432-436.  
37  
38  
39  
40 35. Nakabayashi H, Taketa K, Miyano K, Yamane T and Sato J (1982) Growth of human  
41 hepatoma cells lines with differentiated functions in chemically defined medium. *Cancer*  
42 *Res* 42:3858-3863  
43  
44  
45  
46  
47 36. Nguyen TN, Wang HJ, Zalzal S, Nanci A and Nabi IR (2000) Purification and  
48 characterization of beta-actin-rich tumor cell pseudopodia: role of glycolysis. *Exp Cell*  
49 *Res* 258:171-183.  
50  
51  
52  
53 37. Olkkonen VM and Li S (2013) Oxysterol-binding proteins: sterol and  
54 phosphoinositide sensors coordinating transport, signaling and metabolism. *Prog Lipid*  
55 *Res* 52:529-538.  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

- 1  
2  
3  
4 38. Peattie DA, Harding MW, Fleming MA, DeCenzo MT, Lippke JA, Livingston DJ  
5 and Benasutti M (1992) Expression and characterization of human FKBP52, an  
6 immunophilin that associates with the 90-kDa heat shock protein and is a component of  
7 steroid receptor complexes. *Proc Natl Acad Sci U S A* 89:10974-10978  
8  
9  
10  
11  
12 39. Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J and  
13 Schulze A (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and  
14 fatty acid biosynthesis via activation of SREBP. *Oncogene* 24:6465-6481.  
15  
16  
17  
18 40. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leever S, Griffiths JR,  
19 Chung YL and Schulze A (2008) SREBP activity is regulated by mTORC1 and  
20 contributes to Akt-dependent cell growth. *Cell Metab* 8:224-236.  
21  
22  
23  
24  
25 41. Puhka M, Vihinen H, Joensuu M and Jokitalo E (2007) Endoplasmic reticulum  
26 remains continuous and undergoes sheet-to-tubule transformation during cell division in  
27 mammalian cells. *J Cell Biol* 179:895-909.  
28  
29  
30  
31 42. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA and Zhang F (2013) Genome  
32 engineering using the CRISPR-Cas9 system. *Nat Protoc* 8:2281-2308.  
33  
34  
35  
36 43. Reed BD, Charos AE, Szekely AM, Weissman SM and Snyder M (2008) Genome-  
37 wide occupancy of SREBP1 and its partners NFY and SP1 reveals novel functional roles  
38 and combinatorial regulation of distinct classes of genes. *PLoS Genet* 4:e1000133. doi:  
39 10.1371/journal.pgen.1000133  
40  
41  
42  
43  
44 44. Salo VT, Belevich I, Li S, Karhinen L, Vihinen H, Vigouroux C, Magre J, Thiele C,  
45 Holtta-Vuori M, Jokitalo E and Ikonen E (2016) Seipin regulates ER-lipid droplet  
46 contacts and cargo delivery. *EMBO J* 35:2699-2716.  
47  
48  
49  
50 45. Sato S, Fujita N and Tsuruo T (2000) Modulation of Akt kinase activity by binding  
51 to Hsp90. *Proc Natl Acad Sci U S A* 97:10832-10837.  
52  
53  
54  
55 46. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P and  
56 Giallongo A (1996) Hypoxia response elements in the aldolase A, enolase 1, and lactate  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible  
5 factor 1. *J Biol Chem* 271:32529-32537  
6

7  
8  
9 47. Suchanek M, Hynynen R, Wohlfahrt G, Lehto M, Johansson M, Saarinen H,  
10 Radzikowska A, Thiele C and Olkkonen VM (2007) The mammalian oxysterol-binding  
11 protein-related proteins (ORPs) bind 25-hydroxycholesterol in an evolutionarily  
12 conserved pocket. *Biochem J* 405:473-480.  
13  
14

15  
16  
17 48. Tong J, Yang H, Yang H, Eom SH and Im YJ (2013) Structure of Osh3 reveals a  
18 conserved mode of phosphoinositide binding in oxysterol-binding proteins. *Structure*  
19 21:1203-1213.  
20  
21

22  
23 49. Usatyuk PV, Fu P, Mohan V, Epshtein Y, Jacobson JR, Gomez-Cambroner J, Wary  
24 KK, Bindokas V, Dudek SM, Salgia R, Garcia JG and Natarajan V (2014) Role of c-  
25 Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor  
26 (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and  
27 motility of lung endothelial cells. *J Biol Chem* 289:13476-13491.  
28  
29

30  
31  
32 50. Weber-Boyvat M, Kentala H, Peränen J and Olkkonen VM (2015) Ligand-dependent  
33 localization and function of ORP-VAP complexes at membrane contact sites. *Cell Mol*  
34 *Life Sci* 72:1967-1987.  
35  
36

37  
38  
39 51. Wilfling F, Wang H, Haas JT, Kraemer N, Gould TJ, Uchida A, Cheng JX, Graham  
40 M, Christiano R, Frohlich F, Liu X, Buhman KK, Coleman RA, Bewersdorf J, Farese  
41 RV, Jr and Walther TC (2013) Triacylglycerol synthesis enzymes mediate lipid droplet  
42 growth by relocating from the ER to lipid droplets. *Dev Cell* 24:384-399.  
43  
44

45  
46  
47 52. Wu N, Zheng B, Shaywitz A, Dagon Y, Tower C, Bellinger G, Shen CH, Wen J,  
48 Asara J, McGraw TE, Kahn BB and Cantley LC (2013) AMPK-dependent degradation of  
49 TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. *Mol Cell*  
50 49:1167-1175.  
51  
52

53  
54  
55 53. Xu N, Zhang SO, Cole RA, McKinney SA, Guo F, Haas JT, Bobba S, Farese RV, Jr  
56 and Mak HY (2012) The FATP1-DGAT2 complex facilitates lipid droplet expansion at  
57 the ER-lipid droplet interface. *J Cell Biol* 198:895-911.  
58  
59  
60  
61  
62

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

54. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, Gorgun C, Kwiatkowski DJ, Hotamisligil GS, Lee CH and Manning BD (2011) Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. *Cell Metab* 14:21-32.

55. Yu Y, Hamza A, Zhang T, Gu M, Zou P, Newman B, Li Y, Gunatilaka AA, Zhan CG and Sun D (2010) Withaferin A targets heat shock protein 90 in pancreatic cancer cells. *Biochem Pharmacol* 79:542-551.

## Figure captions

**Fig. 1.** ORP2-KO disturbs Akt signaling. (A) The Akt signaling components dysregulated in the transcriptome of ORP2-KO cells are shown in green (for up-regulation) or red (for down-regulation). (B) Relative mRNA expression of Akt signaling components in ORP2-KO versus control cells (values for Cas9 controls were set at 0) analyzed by RNA sequencing of three replicate cultures. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  (after BH adjustment).

**Fig. 2.** ORP2-KO inhibits Akt phosphorylation and ORP2 interacts with the Cdc37–Hsp90–Akt effector complex. (A) Western blot analysis of Akt(Ser473) and GSK-3 $\beta$ (Ser9) after 2 h serum starvation followed by an additional 8 min incubation with 100 nM insulin added in the starvation medium. Data is shown for native HuH7 cells, Cas9 control cells and the ORP2 knock-out cell line. (B) Western blot analysis of Akt(Ser473) and GSK-3 $\beta$ (Ser9) under basal culture conditions or after 8 min incubation with 100 nM insulin added in the basal medium. The ORP2 knock-out cell lines are indicated as KO1, KO2, and the Cas9 controls as Cas9. (C) Quantification of Akt(Ser473) phosphorylation. The data represents four independent western blots of independent cultures similar to that shown in (B). (D) Quantification of the relative GSK-3 $\beta$ (Ser9) phosphorylation from four independent western blots of independent cultures similar to that shown in (B). (E) Western blot quantification of Akt(Ser473) phosphorylation in HUVECs silenced with ORP2 specific shRNA (shORP2) or shRNA control (shCTRL) followed by an epidermal growth factor stimulation [(EGF) 30 ng/ml for 10 min]. The data represents three independent western blots of independent cultures. (F) HuH7 cells were lysed and subjected to GST-ORP2 pull-down. Cell lysates (L) and pull-downs (PD) were analyzed by western blotting with anti-Cdc37, anti-Hsp90 and anti-Akt antibodies. Plain GST was used as a negative control. (G) GST-ORP2 pull-down of HuH7 cells treated with 5  $\mu$ M Withaferin A. Cell lysates (L) and pull-downs (PD) were analyzed by western blotting with anti-Cdc37, anti-Hsp90 and anti-Akt antibodies. (H) GST-ORP2 pull-down from HuH7 cell lysates treated with lambda protein phosphatase ( $\lambda$ -PP). Cell lysates (L) and pull-downs (PD) were analyzed by western blotting with anti-Akt antibody. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  (Student's T-test).



1  
2  
3  
4 **Fig. 3.** ORP2 co-localizes with Akt(Ser473) and Cdc37 at lamellipodia. (A) HUVECs  
5 transfected with GFP-ORP2, stimulated with 100 nM insulin for 2 min and stained with  
6 Cdc37 [1:100 dilution (Thermo Scientific)] and Akt(Ser473) [1:25 dilution (Cell  
7 Signaling)] antibodies and DAPI. (B) HUVECs transfected with GFP-ORP2, stimulated  
8 with 100 nM insulin for 2 min and stained with Akt(Ser473) and cortactin [10 µg/ml  
9 (Merck-Millipore)] antibodies and DAPI. (A) HUVECs transfected with GFP-  
10 ORP2(mFFAT), stimulated with 100 nM insulin for 2 min and stained with cortactin  
11 antibody [10 µg/ml (Merck-Millipore)] and DAPI.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22 **Fig. 4.** ORP2-KO inhibits glucose uptake, glycogen synthesis, and glycolysis. (A)  
23 Quantification of [<sup>3</sup>H]-2-Deoxy-D-glucose uptake into ORP2-KO and Cas9 control cells  
24 during 15 min. Shown in a relative scale are averages of four independent experiments  
25 each performed as four replicates. (B) Quantification of D-[U-<sup>14</sup>C]-glucose incorporation  
26 into glycogen in ORP2-KO and control cells during 1 h. Shown in a relative scale are  
27 averages of three independent experiments each performed as three replicates. (C)  
28 Quantification of D-[U-<sup>14</sup>C]-glucose incorporation into glycogen during 1 h in ORP2-KO  
29 control cells infected with an empty lentiviral vector (ctrl) or a lentivirus overexpressing  
30 ORP2 (ORP2 oex). Shown are averages of two independent experiments both performed  
31 as five replicates. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 (Student's T-test). (D) Schematic  
32 model of the glycolytic pathway and its enzymes down-regulated in the ORP2-KO cells.  
33 (E) Relative expression of glycolytic genes in ORP2-KO versus control cells (Cas9  
34 controls were set at 1) analyzed by RNA sequencing of four replicate cultures. \*p<0.05,  
35 \*\*p<0.01, \*\*\*p<0.001 (after BH adjustment). (F) Extracellular acidification rate (ECAR)  
36 after glucose, Oligomycin and 2-deoxy-D-glucose (2-DG) injections of control and  
37 ORP2-KO cells measured with a Seahorse XFe96 analyzer in four independent  
38 measurements each as 12 replicates. (G) Calculation of the average glycolysis rate from  
39 the measurements shown in (F) by reducing the non-glycolytic acidification from the  
40 maximum ECAR before Oligomycin injection; \*p<0.05, \*\*p<0.01, \*\*\*p<0.001  
41 (Student's T-test). Abbreviations: PGK1, phosphoglycerate kinase 1; GAPDH,  
42 glyceraldehyde-3-phosphate dehydrogenase; ALDOA, fructose-bisphosphate aldolase A;  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 ENO, enolase; PKM, pyruvate kinase; PGAM1, phosphoglycerate mutase 1; TPI1, triose  
5 phosphate isomerase 1; PFKFB, 6-phosphofructo-2-kinase; GP1, glucose-6-phosphate  
6 isomerase.  
7  
8  
9



10 **Fig. 5.** ORP2 knock-out reduces the TG content and modifies the expression of TG  
11 metabolic genes of hepatoma cells. (A) ORP2-KO and control cells' TG content was  
12 assessed by thin-layer chromatography. Shown is mean of five replicate cultures. (B) TG  
13 synthesis was measured in ORP2-KO and control cells by [<sup>3</sup>H]-oleic acid labeling for 3 h.  
14 Shown is mean of two independent experiments each performed as four replicates. (C)  
15 Quantification of [<sup>3</sup>H]-palmitic acid uptake into ORP2-KO and control cells during 15  
16 min. Shown in a relative scale are averages of two independent experiments each  
17 performed as four replicates. (D) Quantification of TG synthesis with [<sup>3</sup>H]-oleic acid  
18 labeling for 3 h in ORP2-KO control cells infected with an empty lentiviral vector (ctrl)  
19 or a lentivirus overexpressing ORP2 (ORP2 oex). Shown are averages of two  
20 independent experiments both performed as five replicates. \*p<0.05, \*\*p<0.01,  
21 \*\*\*p<0.001 (Student's T-test). (E) Relative mRNA expression of SREBP-1 and its target  
22 genes in ORP2-KO versus control cells (values for Cas9 controls were set at 1) analyzed  
23 by RNA sequencing of four replicate cultures. (F) Relative gene expression of TG  
24 metabolic genes in ORP2-KO cells versus control cells (Cas9 controls were set at 1)  
25 analyzed by RNA sequencing of four replicate cultures. The statistical analysis of the  
26 RNA sequencing data is specified in Material and methods, section 'RNA sequencing  
27 and pathway analysis'. \*p<0.05, \*\*p<0.01, \*\*\*p<0.001 (after BH adjustment).  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 **Fig. 6.** ORP2-KO does not reduce ER-LD contact sites but affects their dynamic  
45 expansion after fatty acid (FA) loading. ORP2-KO and control cells were either grown in  
46 basal culture medium or loaded for 3 h with FA as described in Materials and Methods.  
47 (A) TEM micrograph from KO2 loaded sample showing modeled LDs (depicted in  
48 purple) and the ER (depicted in yellow) that is in close vicinity to intact LDs. The ER-LD  
49 contact sites that are within 30 nm distance are shown with green lines. Scale bar 500 nm.  
50 (B) Total LD area per cell. (C) Total length of ER-LD contacts per cell. The data  
51 represents mean ± SEM from 16–32 cells, with 4 images from each analyzed; \*/#p<0.05,  
52 \*\*/##p<0.01, \*\*\*/###p<0.001 (Student's T-test); \* indicates significant difference  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


1  
2  
3  
4 between unloaded and loaded cells, and # indicates significant difference between Cas9  
5 ctrl and ORP2-KO cells.  
6  
7

8  
9 **Fig. 7.** A schematic model of ORP2 function in Akt signaling. Akt signaling is activated  
10 by extracellular growth factors (e.g. insulin), which binds to plasma membrane (PM)  
11 growth factor receptors (GFR) resulting in activation of intracellular PI3-kinase (PI3K).  
12 PI3K phosphorylates PIP<sub>2</sub> to PIP<sub>3</sub>, triggering a PM recruitment of phosphoinositide-  
13 dependent kinase-1 (PDK1) and Akt. The protein kinases (PI3K/PDK1/Akt) are  
14 scaffolded by IQGAP1 which interacts with ORP2. At PM, Akt interacts with its effector  
15 complex Hsp90-Cdc37-ORP2 and is phosphorylated by PDK1. Active Akt regulates the  
16 activity of several downstream target molecules (e.g. GSK3), resulting in increased  
17 uptake of glucose, glycogen synthesis, glycolysis, lipogenesis via SREBP-1 and  
18 migration of cells.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65


# Figure 1




## Figure 2



# Figure 3




# Figure 4





## Figure 5





## Figure 6






Figure 7





Supplemental method description and captions for the supplemental figures



[Click here to access/download](#)

**Supplementary Material**


Kentala et al\_Supplemental materials.docx
















Click here to access/download  
**Supplementary Material**  
FigureS1.tif






Click here to access/download  
**Supplementary Material**  
FigureS2.tif







Click here to access/download  
**Supplementary Material**  
FigureS3.tif

